I intend in this paper to put before you a few ideas as a basis for discussion rather than to deal with the mathematical formula of project selection. Project selection in the pharmaceutical industry is a complex subject and is very much related to the philosophy of the company concerned and the historical basis for its research.
The research programme of a company is merely a photograph of the situation at a particular point in time, and the way in which a company's research has evolved may depend on many factors. Although in my own organization I review the research programme in great detail every year you will not be surprised to learn that major changes do not occur annually and it is only on rare occasions that a new project is introduced or indeed that an existing project is terminated, and such changes only take place after a great deal of study of the technical and financial factors. Having started a new project with carefully defined objectives, I would be prepared to let it run for some ten years with careful monitoring, at least twice yearly by myself, before I became anxious about the nonappearance of a product candidate. In setting up a new project it might take one to two years to recruit and train the staff required (assuming that they were not being diverted from an existing project) and possibly up to 3-3k years from the start to produce the experimental models required to test compounds.
Probably the most important factor in project selection today is the supply of money available for research. Unlike governments which rely on taxation or on borrowing to maintain their research, the pharmaceutical company must rely on the profits generated from the sales of its own products to cover its research expenditure. This leads to resources being devoted to research of a defensive nature designed to protect those product areas which have themselves generated the money which is used by research.
As money is a limiting factor, no company can tackle the complete range of diseases which affect man, and therefore project selection is required. The number of projects and the depth to which they can be investigated depend on the size of the company and the financial resources which it has decided to allocate to research. The need to export has affected our choice of projects to some extent, and the pharmaceutical industry has made a considerable contribution to the balance of payments. If we are allowed to expand profitably then I am sure the choice can be widened and the less common diseases tackled. In the meantime I welcome any opportunity presented to look at collaborative research with any other body. I also welcome the opportunity presented by this Forum to discuss these problems and look for solutions. Such solutions must remain in the hands of the pharmaceutical industry and our colleagues in medicine, and be protected from the doctrinaire approach of the politician. It is accepted that research is a very high-risk activity, at least as far as the discovery of genuine new active drugs is concerned -both on account of the high uncertainty of its outcome and the considerable lead times involved. In spite of this it is to research fhat the internationally based drug company looks for its major revenueearning products. Because of the key role of research in the success of the company as a whole the level of investment and selection of fields of research represents crucial decisions for research and development management.
The overall failure rate of compounds between synthesis and the market is, of course, very highthe National Economic Development Office study in 1972 assessed the failure rate at 99.99%. However, the time scale involved is perhaps of even greater importance in selecting areas for future research.
Today it takes about 15 years frsom the original idea or concept to the widespread use of a new drug. The initial investigational studies are almost invariably based on some known basic or scientific or medical knowledge so that to project too far ahead of existing frontiers would be unprofitable. Hence about 20 years is an appropriate time span over which to consider the selection of research projects in the pharmaceutical industry. The key factor in any selection for research areas should be the future medical and social need for new drugs. Therefore a prerequisite must be an estimate of the medical and social needs some 20 years hence in order that (irrespective of which research project is chosen) the conceptual ideas of the present are appropriate and geared to this future. One is led, therefore, to the inescapable conclusion that the new drugs in the twenty-first century will originate from ideas in the next few years. From a research point of view, the year 2000 is almost upon us.
It is not appropriate here to discuss in depth the various routes by which new drugs are obtained; the relative emphasis placed on them is a combination of individual research philosophy and the particular needs of a given pharmaceutical company, and I will deal later with our .own particular research philosophy.
It is not easy to predict specific future events, i.e. medical and social wants in the year 2000, but there have been several publications of such
